March 05, 2014

In re: Galena Biopharma, Inc. Securities Litigation

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. December 04, 2015

    Galena To Pay $20M To End Investor Suits Over Deceptive PR

    Galena Biopharma Inc. and its brass have agreed to pay $20 million to settle a securities class action and a derivative suit accusing them of inflating the company's share price with a misleading marketing campaign and committing insider trading, the pharmaceutical maker announced on Friday.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS